A Phase 1 Study of JNJ-78306358, a T Cell Redirecting Bispecific Antibody Targeting HLA-G for Advanced Stage Solid Tumors
Latest Information Update: 09 Aug 2024
At a glance
- Drugs JNJ-78306358 (Primary)
- Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 06 Aug 2024 Results assessing the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of JNJ-78306358 in patients with advanced solid tumors were published in the Cancer Immunology Immunotherapy.
- 24 Oct 2023 Results (n=39) presented at the 48th European Society for Medical Oncology Congress.
- 23 Feb 2023 Status changed from active, no longer recruiting to completed.